TY - JOUR
T1 - Quantitative targeted proteomics for understanding the blood-brain barrier
T2 - Towards pharmacoproteomics
AU - Ohtsuki, Sumio
AU - Hirayama, Mio
AU - Ito, Shingo
AU - Uchida, Yasuo
AU - Tachikawa, Masanori
AU - Terasaki, Tetsuya
N1 - Funding Information:
The studies mentioned in this review were supported in part by a Grant for Development of Creative Technology Seeds Supporting Program for Creating University Ventures and a grant for Creation of Strategic Innovation Project from the Japan Science and Technology Agency (JST), and the Industrial Technology Research Grant Program from New Energy and the Industrial Technology Development Organization (NEDO) of Japan, as well as the funding program for Next Generation World-Leading Researchers by the Cabinet Office, Government of Japan.
PY - 2014/6
Y1 - 2014/6
N2 - The blood-brain barrier (BBB) is formed by brain capillary endothelial cells linked together via complex tight junctions, and serves to prevent entry of drugs into the brain. Multiple transporters are expressed at the BBB, where they control exchange of materials between the circulating blood and brain interstitial fluid, thereby supporting and protecting the CNS. An understanding of the BBB is necessary for efficient development of CNS-acting drugs and to identify potential drug targets for treatment of CNS diseases. Quantitative targeted proteomics can provide detailed information on protein expression levels at the BBB. The present review highlights the latest applications of quantitative targeted proteomics in BBB research, specifically to evaluate species and in vivo-in vitro differences, and to reconstruct in vivo transport activity. Such a BBB quantitative proteomics approach can be considered as pharmacoproteomics.
AB - The blood-brain barrier (BBB) is formed by brain capillary endothelial cells linked together via complex tight junctions, and serves to prevent entry of drugs into the brain. Multiple transporters are expressed at the BBB, where they control exchange of materials between the circulating blood and brain interstitial fluid, thereby supporting and protecting the CNS. An understanding of the BBB is necessary for efficient development of CNS-acting drugs and to identify potential drug targets for treatment of CNS diseases. Quantitative targeted proteomics can provide detailed information on protein expression levels at the BBB. The present review highlights the latest applications of quantitative targeted proteomics in BBB research, specifically to evaluate species and in vivo-in vitro differences, and to reconstruct in vivo transport activity. Such a BBB quantitative proteomics approach can be considered as pharmacoproteomics.
KW - absolute quantification
KW - blood brain barrier
KW - brain capillary endothelial cells
KW - multiple reaction monitoring
KW - pharmacoproteomics
KW - quantitative targeted proteomics
KW - transporter
UR - http://www.scopus.com/inward/record.url?scp=84901056306&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901056306&partnerID=8YFLogxK
U2 - 10.1586/14789450.2014.893830
DO - 10.1586/14789450.2014.893830
M3 - Review article
C2 - 24702234
AN - SCOPUS:84901056306
VL - 11
SP - 303
EP - 313
JO - Expert Review of Proteomics
JF - Expert Review of Proteomics
SN - 1478-9450
IS - 3
ER -